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Abstract
Introduction: There is a remarkable increase in cardiovascular disease after menopause. On the other hand,
metabolic syndrome as a collection of risk factors has a known effect on cardiovascular diseases. Hormone changes
are considered as one of the main relevant factor regarding cardiovascular disease as well as some recognized
relationship with metabolic syndrome’s components. This study was carried out in order to search for prevalence
of metabolic syndrome during menopausal transition.
Method: In a cross sectional study in urban and rural areas of Isfahan, Najafabad and Arak cities, 1596 women
aged more than 45 years were investigated using Isfahan Healthy Heart Program’s (IHHP) samples. Participants
were categorized into three groups of pre-menopause, menopause and post-menopause. Leisure time physical
activity and global dietary index were included as life style factors. The association of metabolic syndrome and its
components with menopausal transition considering other factors such as age and life style was analyzed.
Results: there were 303, 233 and 987 women in premenopausal, early menopausal and postmenopausal groups
respectively. Metabolic syndrome was found in 136(44.9%) premenopausal participants and significantly increased
to 135(57.9%) and 634(64.3%) in early menopausal and postmenopausal participants respectively, when age was
considered (P = 0.010). Except for hypertension and hypertriglyceridemia, there was no significant difference
between three groups of menopausal transition when metabolic syndrome’s components were considered.
Conclusion: In contrary to the claims regarding the role of waist circumference and blood glucose in increasing of
metabolic syndrome during the menopausal transition, this study showed this phenomenon could be
independence of them.
Introduction
Today, cardiovascular disease is one of the main causes
of mortality of women in the world [1]. Considering the
metabolic changes that occur in women during post
menopause (PM), there is an increase in risk factors of
cardiovascular diseases (CVD) and incidence of these
diseases in PM [2]. There are different points of view
about incidence of CVD during PM period and their
relationship. Some believe that the increased incidence
occurs just by increased age but some studies such as
Framingham demonstrated the fourfold increase in inci-
dence of CVD in PM period [3]. Moreover, the inci-
dence of CVD increases in patients with premature
menopause or those who underwent surgeries that
result in menopause [4]. Metabolic syndrome (MetS) is
a cluster of components which make the individual sus-
ceptible to CVD. These components are: increased lipid
accumulation in central parts of the body (abdominal
obesity), insulin resistance (IR), dyslipidemia (elevated
triglyceride and LDL and decreased HDL), and hyper-
tension. According to NCEP-ATP III criteria (National
Cholesterol Education Program- Adult Treatment Panel
III), presence of at least three o three components in
considered MetS [5]. Various studies have shown that
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any medium, provided the original work is properly cited.being affected by MetS increases the risk of CVD as well
as morbidity of the disease [6].
Increased incidence of MetS during PM period has
been shown in many studies throughout the world [7,8].
A sixty percent increased risk of MetS and increased
incidence of MetS after adjusting various background
factors is observed in PM [9]. The etiology of MetS is
not clearly defined, but it is shown that the syndrome is
associated with visceral obesity [10]. Thus, the theory of
metabolic changes during PM and increased abdominal
obesity as a result of decrease in estrogen is one of the
hypotheses which explain the increased incidence of the
syndrome during this period [11]. Concerning the preva-
lence of CVD in women (about 22%) [12,13] and the
prevalence of MetS (35-58%) in Iran [14,15], this study
is aimed at determining the prevalence of the syndrome
and its components in PM period and comparing it
with that of the pre-menopause and menopause period.
Method
The survey was conducted in 3 cities in the central part
of Iran (Arak, Isfahan and Najafabad) as baseline survey
of Isfahan Healthy Heart Program. The subjects were
selected using multi-stage random sampling with clus-
ters in the urban and rural areas. The project team con-
ducted the baseline survey of 12,514 adults aged≥19
years. The number of individuals was in accordance
with the total population of the 3 cities and clusters.
Having resided for more than 10 years in these cities,
not being pregnant for females and being mentally
healthy were the criteria for participating in this study.
Written informed consent was obtained from subjects
after full explanation of the procedure involved. The
study was approved by the ethics committee of the Isfa-
han University of Medical Sciences. The details of the
program have previously reported elsewhere [16].
Initially, a questionnaire was completed at each sub-
ject’s home by trained nurses.
It contained demographic information, smoking,
menopausal status, consumption of relevant medica-
tion especially anti-diabetic agents, anti-hypertensive
agents and hormone replacement therapy. In addition,
food frequency questionnaire and a questionnaire for
leisure time behavior were used for participants. After-
ward, participants were invited to certain health cen-
ters, where blood samplings and clinical check-ups
after 12 to 14 hour fasting were carried out. In addi-
tion to fasting blood glucose (FBG), 2-hour plasma
glucose (2hPG) was also measured after 2 hours and
after consumption of 75 g of glucose. Serum lipids,
including total cholesterol (TC) and triglyceride (TG),
were also measured using the relevant fasting blood
sample. All the blood sampling procedures were per-
formed in the central laboratory of the Isfahan
Cardiovascular Research Center using the enzyme-
linked method. Subjects were weighed with light
clothes and no shoes, and their waist and hip measure-
ment and weight were also noted. In addition, waist
circumference (WC) was measured at a level midway
between the lower rib margin and the iliac crest to the
nearest half-centimeter. The blood pressures of the
individuals were measured twice with a standard bar-
ometer, with the subjects in a sitting position, and the
average blood pressure was taken into consideration.
The subjects of the present study were 1596 women,
among all participants of the IHHP, who were classi-
fied into three groups: premenopausal women, aged 40
and over and still menstruate, early menopausal
women with a permanent cessation of menses (sponta-
neous or surgical) of over 12 months and less than 3
years, and postmenopausal women who had at least a
3-year history of cessation of menses (spontaneous or
surgical). The 44(2.8%) smokers and those currently
used hormone replacement therapy 29(1.8%) were
excluded the same as one other study did [26]. No par-
ticipants used oral contraceptive pill or other hormone
replacement therapy.
A modified definition by the Adult Treatment Panel
III guideline of the National
Cholesterol Education Program16 was used to cate-
gorize the subjects according to the number of compo-
nents of the metabolic syndrome. The metabolic
syndrome was defined as the presence of 3 or more of
the following components: 1) serum triglycerides ≥150
mg/dL; 2) HDL cholesterol ≤50 mg/dL; 3) glucose ≥100
mg/dL fasting or on treatment; 4) blood pressure ≥130/
85 mmHg or anti hypertensive medication use, and 5)
waist circumference ≥88 cm [10] The 2001 definition
identified fasting plasma glucose of ≥110 mg/dL as ele-
vated. This was modified in 2004 to be ≥100 mg/dL, in
accordance with the American Diabetes Associations
updated definition of impaired fasting glucose (IFG)
[17]. Considering physical activity, the period and fre-
quency of doing each specific activity as leisure in a
week were asked. Leisure time physical activity was cal-
culated in the unit of Mets minutes per day using extent
coefficients of each particular activity [18] multiplying
duration of performing it in a day. One MET is reflec-
tive of energy expenditure during rest [19]. Dietary
behaviors were assessed with a validated, qualitative,
forty-eight-item FFQ. The FFQ was adapted from the
CINDI programme questionnaire [20]. A global dietary
index (GDI), expressing global diet quality, was created
by calculating the average of the mean of twenty-nine
frequency questions in seven categories. Higher scores
on the GDI represent diets higher in total fat, saturated
fat and cholesterol. More details were depicted else-
where [21].
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Data entry was carried out using EPI info™.A l ld a t a
were analyzed by SPSS (SPSS Inc, Chicago, IL, USA;
Version 15). The averages are reported as Mean ± SD.
For all analyses, statistical significance was assessed at a
level of 0.05 (2-tailed). In General Linear Model (GLM),
menopausal status was inserted as fixed factor and age
as covariate to determine the relationship of quantitative
variables (as dependent factors) and menopausal status.
ANOVA with Tukey Post Hoc test was used to verify
exactly in which three levels there were statistically sig-
nificant differences. In the case of variables without nor-
mal distribution shape (like FBG), nonparametric tests
were carried out as well but no important differences
were shown. Logistic Regression analysis was used to
find out whether menopausal status can predict the pre-
sence of metabolic syndrome or its components when
other effective factors such as age were included in the
models.
Results
Table 1 shows age adjusted relationship of metabolic
syndrome risk factors, other biomarkers and medica-
tions with menopausal status. Systolic and diastolic
blood pressure increased significantly from premenopau-
sal to early menopausal status and continued to increase
toward postmenopausal status. Considering total choles-
terol, LDL-C and triglyceride, early menopausal and
postmenopausal status did not yield significant differ-
ence but the values in both were significantly higher in
comparison to premenopausal status.
Figure 1 shows the percentage of metabolic syndrome
and its components in menopausal transition. Metabolic
syndrome was found in 136(44.9%) premenopausal par-
ticipants and significantly increased to 135(57.9%) and
634(64.3%) in early menopausal and postmenopausal
participants respectively (P < 0.001). This association
remained significant after adjusting for age (P = 0.010).
Early menopausal status increased risk of metabolic
syndrome by 1.64 times
(1.10-2.43, 95%CI) and the odds ratio for postmeno-
pausal status was 1.68 (1.15- 2.45) in comparison to pre-
menopausal status when adjusted for age, Global Dietary
Index and Leisure Time Physical Activity. However, only
triglyceride and blood pressure components of meta-
b o l i cs y n d r o m ew e r es i g n i f i cantly associated with early
menopausal status when the relationships were adjusted
for age. Considering Triglyceride component of meta-
bolic syndrome as dependent variable, adjusted Odds
Ratio were 2.56(1.68-3.90) and 1.92(1.31-2.83) for early
menopausal and postmenopausal status respectively (P <
0.001). On the contrary, for blood pressure the early
menopausal status did not contribute significantly to the
model when it was adjusted for GDI, leisure time physi-
cal activity and age. The model including anti diabetic
drug did not change non significant association of FBG
and menopausal state. The participants came from both
urban and rural areas. The prevalence of metabolic syn-
drome in urban area was 48.9%, 62.7% and 66% in pre
menopausal, early menopausal and postmenopausal
groups respectively while these percentages in rural area
were 33.7%, 46.4 and 59.5% respectively (P < 0.001 for
Table 1 Age adjusted association of metabolic syndrome and other related biomarkers in menopausal transition
(mean ± SD)
Variables Pre-menopausal (n = 303) Menopausal (n = 233) Post-menopausal (n = 987) P value*
Age (years) 47.2 ± 2.1 51.5 ± 5.8 61.6 ± 8.5 < 0.001
Systolic blood pressure (mmHg) 120.2 ± 20.2 125.2 ± 23 132.4 ± 22.1 0.030
Diastolic blood pressure (mmHg) 77.8 ± 11.8 80.3 ± 12.8 82.5 ± 11.8 0.008
Fasting plasma glucose (mg/dl) 88.7 ± 29.7 91.2 ± 34 95.1 ± 38.2 0.393
§
2 h-post-prandial glucose (mg/dl) 115 ± 53.4 121 ± 67.4 127.3 ± 70.2 0.011
§
Total Cholesterol (mg/dl) 209.8 ± 44.6 233.6 ± 54.6 233.3 ± 50.6 < 0.001
†
LDL-C (mg/dl) 127.2 ± 38.2 142.8 ± 47.3 142.5 ± 43.5 0.004
†
Triglycerides (mg/dl) 176.1 ± 98.9 213.7 ± 118.1 207.8 ± 104.9 < 0.001
†
HDL-C (mg/dl) 48.3 ± 10.1 50.4 ± 11 49.5 ± 10.8 0.121
Waist (cm) 97.6 ± 12.5 97.2 ± 13.4 98.5 ± 12.3 0.197
Waist to hip ratio 0.92 ± 0.07 0.93 ± 0.08 0.95 ± 0.07 0.391
Body mass index 28.6 ± 4.7 28.3 ± 5.1 27.6 ± 4.5 0.932
Anti diabetes medication 12(4%) 13(5.6%) 115(11.7%) 0.003
Anti hypertension medication 35(11.6%) 48(20.6%) 324(32.9%) 0.153
Global Dietary Index 0.90 ± 0.23 0.87 ± 0.23 0.84 ± 0.27 0.630
Leisure Time Physical Activity 62.40 ± 82.37 66.19 ± 88.04 62.09 ± 82.54 0.482
* Age adjusted P-value § Adjusted for Anti diabetes medication in addition to age
†Post hoc test did not find significant relationship between early menopausal and Post- Menopausal group
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tive factor for metabolic syndrome and decreased it 0.67
(0.53-9.84) times but adjusted model for area yielded
n e a r l yt h es a m ea s s o c i a t i o nbetween menopausal status
and metabolic syndrome. Moreover, the interaction of
menopausal status and area of residence was insignifi-
cant (P = 0.296).
Discussion
As our results show, the prevalence of MetS in the PM
women has increased significantly in comparison with
menopause and pre-menopause period, even after age
adjustment. Moreover, regarding the components of
MetS, a significant increase was observed in the fre-
quency of PM women with hypertrigyceridemia and
hypertension. However, no significant difference was
observed among fasting blood glucose, HDL, and waist
circumference (abdominal obesity) with menopausal sta-
tus when age was included in the model. As all analyses
were age adjusted, it means that no further differences
other than what was attributable to age were found in
these items. The change in metabolic status of the body
and the type of fat substitution in different tissues is
one of the theories about the incidence of MetS during
PM. In pre-menopausal women, fat accumulates in
lower extremities to a great extent as a result of estro-
gen secretion. During menopause the pattern of hor-
mone secretion changes and gradually causes fat
accumulation in visceral tissues of abdomen and as a
result, central obesity [22]. Many metabolic changes in
PM women are related to estrogen secretion decrease
and consequent accumulation of abdominal fat. To
decrease the risk of MetS and also CVD in PM women,
life style modification to control weight, lipid profile,
blood pressure and blood glucose is recommended.
Besides the abdominal obesity, changes in lipid profile
and also insulin resistance are two important factors
that are influenced by hormone secretion decrease.
However, this is the question: does estrogen have a pri-
mary role in MetS incidence or it only masks the
Figure 1 Age adjusted metabolic syndrome components and metabolic syndrome in menopausal transition (age adjusted P-value for
comparison of differences between pre menopause, menopause and post menopause groups).
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[3,23]. A longitudinal study indicated that weight gain is
one of the main changes in PM women. Also, relation-
ship between FSH level and waist circumference
increase with the incidence of abdominal obesity has
been shown [24]. A nine-year cohort study in various
ethnic groups demonstrated that 13.7% of women were
affected by MetS in menopause period and all compo-
nents of MetS changed significantly in the studied
women after menopause. This study demonstrated that
occurrence of MetS in PM women was the result of tes-
tosterone hormone secretion and changes in all compo-
nents of MetS [25].
In another study, women going pass the menopausal
transition experience harmful change in inflammatory
mediators and adipokines with visceral obesity [26].
Matthews et al showed increase in lipoproteins at time
of menopause [27].
These studies can be reasons for the higher prevalence
of MetS by menopause.
Furthermore, Tehran Lipid and Glucose Study (TLGS)
showed that the incidence of MetS during PM period as
well as all components of MetS in menopausal transi-
tion period increase [28].
Nevertheless, results of our study demonstrate that
although there was not significant difference in abdom-
inal obesity and most components of MetS in the stu-
dies women, the risk of MetS increased in menopausal
transition period. This finding is different from the
results of most studies which indicate that metabolic
changes and consequent lipid accumulation and blood
glucose changes during PM are responsible for MetS. In
spite of similarities between the incidence of MetS inci-
dence in menopausal transition period in TLGS and this
study, the changes of mean value of metabolic syndrome
components in two studies did not follow the same pat-
tern. TLGS did not study the components of MetS as
qualitative variables. In addition, the sampled population
in this study came from a greater area which covered
both urban and rural population, while in TLGS sam-
pling was done only in a part of Tehran. Prevalence of
MetS in this study was higher than seen in western
countries in both sexes (20.9% of men had MetS that
not shown). The etiology of it explained in Sarrafzade-
gan et al study [29]. One of the advantages of this study
is studying life style of the three studies groups of
women to investigate the effect of this factor on inci-
dence of MetS and its components. Some previous stu-
dies did not include this aspect. The three groups were
not different, considering physical exercise and nutrition
index in menopausal transition independent of age.
Moreover, adding the two main factors of life style
and age to the model of estimating the risk of MetS did
not change the risk in menopausal and postmenopausal
period. This is indicative of independence MetS of age
and life style.
In addition, of the components of MetS, only hypertri-
glyceridemia was significantly in accordance with this
model. However, among the quantitative variable with-
out being adjusted for nutrition and physical exercise,
only mean blood pressure and triglyceride level changes
reached the significant level.
Absence of significant difference in incidence of MetS
components except for one of them and the significant
difference of incidence of MetS in the three groups indi-
cate that MetS is something more than the simple clus-
tering of the factors.
This is one of the few studies which show no differ-
ence in obesity and fasting blood glucose independent
of age between premenopausal and post menopause.
This finding suggests that besides the aforementioned
factors, other effective factors such as genetic or envir-
onmental ones contribute to the pathogenesis of the dis-
ease, which shows their effect in various ethnic groups
differently. As it was suggested in the study fulfilled by
Carr, it can be mentioned that the presence of estrogen
have a genetic masking effect, rather than a primary role
in MetS control. Thus, the role will be removed by elim-
ination of estrogen and the incidence of MetS will be
increased, in spite of absence of central obesity [3].
Considering some differences between the findings of
current study with results of other studies and shortage
of similar studies in Middle East, carrying out longitudi-
nal studies on women of different ethnic groups in dif-
ferent regions and study of MetS and its components in
menopausal transition in addition to genetic, hormonal,
climactic, and environmental factors can lead to a better
understanding of the above mentioned phenomena.
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